Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) has announced participation in several upcoming investor and scientific conferences. Key events include the mRNA-Based Therapeutics Summit on July 13-14, 2021, and the Ladenburg Thalmann 2021 Healthcare Conference also on July 13, followed by the Cell-Mediated Therapies for Infectious Disease Summit on July 22, 2021. This highlights Arcturus' focus on advancing its mRNA vaccine programs for various diseases. More details and links can be found on their Investor Relations page.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage company specializing in messenger RNA therapies, has announced its participation in several upcoming conferences. These include the BIO Digital 2021 on June 10, 2nd Annual RNAi-Based Therapeutics Summit on June 17, SVB Leerink CybeRx Series: Vaccine Forum on June 21, and 2021 RNA Therapeutics Symposium on June 24. Arcturus focuses on infectious disease vaccines and treatments for rare liver and respiratory diseases, showcasing a diverse pipeline and extensive patent portfolio.
Primordial Genetics announced an exclusive license agreement with Arcturus Therapeutics Holdings Inc. (ARCT) for a novel RNA polymerase enzyme, aimed at enhancing the manufacturing of long, high-quality RNAs for therapeutic use. This collaboration is expected to significantly improve the efficiency and cost-effectiveness of mRNA production, which is vital for drug and vaccine development. Primordial's technology emphasizes innovative RNA manufacturing processes that could lead to advancements in pharmaceuticals, ultimately aiming to address pressing health needs.
Arcturus Therapeutics (Nasdaq: ARCT) reported Q1 2021 financial results, noting revenue of $2.1 million, down from $2.6 million year-over-year. The company incurred a net loss of $56.3 million, reflecting an increase in operating expenses to $59.8 million, driven by higher R&D costs for its ARCT-021 COVID-19 vaccine candidate. The Phase 2 trial for ARCT-021 has completed enrollment with promising interim immunogenicity data supporting plans for a Phase 3 study. Cash reserves are strong at $466.9 million, expected to cover operations for over two years.
Arcturus Therapeutics Holdings (Nasdaq: ARCT) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET on the same day. The company focuses on mRNA medicines targeting infectious diseases and rare liver and respiratory diseases. Arcturus has a diverse pipeline including vaccines for SARS-CoV-2 and influenza, as well as programs for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor and scientific conferences. Highlights include:
- Guggenheim Healthcare Talks: April 1, 2021, at 4:00 p.m. ET (Panel Discussion)
- 7th Annual Truist Securities Life Sciences Summit: May 4, 2021, at 1:50 p.m. ET (Fireside Chat)
- Genetic Vaccine Development Summit: May 20, 2021, at 1:30 p.m. ET (Presentation)
Details and presentation links are available on their website.
Arcturus Therapeutics Holdings Inc. (ARCT) reported its 2020 financial results, showing total revenues of $9.5 million, a significant decline from $20.8 million in 2019. The company incurred a net loss of $72.1 million for the year, compared to $26.0 million in the previous year. Despite this, Arcturus is advancing its ARCT-021 COVID-19 vaccine into Phase 3 trials and has received $46.6 million to support its vaccine stockpiling. The company expects its cash position of $463 million to sustain operations for over two years.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the acquisition of an exclusive license from Alexion Pharmaceuticals for patent-pending nucleic acid purification technologies. This strategic move aims to enhance the production efficiency of mRNA, critical for the development of vaccines and therapies. With this technology, Arcturus can scale up mRNA production while ensuring higher purity. This acquisition strengthens Arcturus' existing intellectual property portfolio, which is vital for its operations in RNA medicines and vaccines, including COVID-19 and Influenza.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the quarter and year ended December 31, 2020, after market close on March 1, 2021. Following this announcement, a conference call and webcast will take place at 4:30 p.m. ET. Arcturus is focused on developing mRNA medicines and vaccines for infectious diseases, with products targeting COVID-19, Influenza, and rare liver and respiratory diseases. The company utilizes its proprietary LUNAR® and STARR™ technologies and is supported by a strong patent portfolio and various collaborations.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a clinical-stage mRNA medicines company, announced its participation in several upcoming investor conferences. Notable events include:
- BIO CEO & Investor Digital Conference: February 12, 2021, at 12:00 p.m. ET
- Raymond James Annual Institutional Investors Conference: March 3, 2021, at 11:40 a.m. ET
- H.C. Wainwright Global Life Sciences Conference: March 9, 2021, at 7:00 a.m. ET
- Barclays Global Healthcare Conference: March 10, 2021, at 1:50 p.m. ET
Arcturus focuses on developing vaccines and treatments for infectious diseases.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
